Link to this page
COVID-19 Ontology
| Preferred Name | Methylprednisolone | |
| Synonyms |
(6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione Veriderm Medrol Methylprednisolone METHYLPREDNISOLONE Caberdelta M Depo-Nisolone Methylprednisolonum Predni-M-Tablinen Depo Moderin 6Alpha-Methylprednisolone DepMedalone methylprednisolone Medrol Veriderm Metilbetasone Solubile Sieropresol Adlone Duralone Emmetipi Esametone Firmacort Medlone 21 Medrate Medrol Medrone Mega-Star Meprolone Metrocort Metypresol Metysolon Prednilen Radilem Solpredone Summicort Urbason Wyacort |
|
| Definitions |
A synthetic corticosteroid with anti-inflammatory and immunomodulating properties. Methylprednisolone binds to and activates specific nuclear receptors, resulting in altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations. |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C647 |
|
| Accepted_Therapeutic_Use_For |
Adrenocortical insufficiency; Conditions requiring immunosuppression; Inflammatory conditions; Multiple Sclerosis; Nephrotic syndrome
|
|
| ALT_DEFINITION |
A corticosteroid hormone replacement.
|
|
| alternative_term |
(6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione Veriderm Medrol Methylprednisolone METHYLPREDNISOLONE Caberdelta M Depo-Nisolone Methylprednisolonum Predni-M-Tablinen Depo Moderin 6Alpha-Methylprednisolone DepMedalone methylprednisolone Medrol Veriderm Metilbetasone Solubile Sieropresol Adlone Duralone Emmetipi Esametone Firmacort Medlone 21 Medrate Medrol Medrone Mega-Star Meprolone Metrocort Metypresol Metysolon Prednilen Radilem Solpredone Summicort Urbason Wyacort
|
|
| CAS_Registry |
83-43-2
|
|
| CHEBI_ID |
CHEBI:6888
|
|
| Chemical_Formula |
C22H30O5
|
|
| code |
C647
|
|
| Contributing_Source |
CTRP FDA
|
|
| definition |
A synthetic corticosteroid with anti-inflammatory and immunomodulating properties. Methylprednisolone binds to and activates specific nuclear receptors, resulting in altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.
|
|
| Display_Name |
Methylprednisolone
|
|
| FDA_UNII_Code |
X4W7ZR7023
|
|
| fromPubMed |
true
|
|
| imported from | ||
| in_subset |
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977 http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978 http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923 http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711 |
|
| label |
Methylprednisolone
|
|
| Legacy_Concept_Name |
Methylprednisolone
|
|
| NSC_Code |
19987
|
|
| oboInOwl:hasDbXRef | ||
| PDQ_Closed_Trial_Search_ID |
41528
|
|
| PDQ_Open_Trial_Search_ID |
41528
|
|
| preferred label |
Methylprednisolone
|
|
| Preferred_Name |
Methylprednisolone
|
|
| prefixIRI |
NCIT:C647
|
|
| prefLabel |
Methylprednisolone
|
|
| Semantic_Type |
Organic Chemical Pharmacologic Substance
|
|
| textual definition |
A synthetic corticosteroid with anti-inflammatory and immunomodulating properties. Methylprednisolone binds to and activates specific nuclear receptors, resulting in altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.
|
|
| UMLS_CUI |
C0025815
|
|
| subClassOf |
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |